Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid to Collaborate with Non-Profit FIND on TB Tests for Developing Countries

NEW YORK, May 23 (GenomeWeb News) - Cepheid said today that it has entered into a collaboration with the non-profit Foundation for Innovative Diagnostics to develop a rapid molecular diagnostic test for tuberculosis.


The test, which will run on Cepheid's GeneXpert system, will detect TB mycobacteria in sputum and determine whether the organisms are drug resistant, the company said.


Cepheid researchers will collaborate with David Alland, a tuberculosis expert at the University of Medicine and Dentistry of New Jersey, on the development of the test, which will be designed to run on Cepheid's GeneXpert System.


FIND is based in Geneva and funded by the Bill and Melinda Gates Foundation. The organization's goal is to develop affordable diagnostic tests for diseases affecting underprivileged populations in developing countries.


According to data from the World Health Organization, TB caused approximately 1.7 million deaths in 2004.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.